# Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TVAX-028 in the Treatment of Chronic Hepatitis B

> **NCT07673068** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Grand Theravac Life Sciences (Nanjing) Co., Ltd.** · enrollment: 32 (estimated)

## Conditions studied

- HBV Infection

## Interventions

- **DRUG:** TVAX-028
- **OTHER:** Adjuvant

## Key facts

- **NCT ID:** NCT07673068
- **Lead sponsor:** Grand Theravac Life Sciences (Nanjing) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-31
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07673068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07673068, "Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TVAX-028 in the Treatment of Chronic Hepatitis B". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07673068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*